KA Schulman, LA Lynn, HA Glick, JM … - Annals of internal …, 1991 - Am Coll Physicians We did a cost-effectiveness analysis of zidovudine therapy for asymptomatic patients with human
immunodeficiency virus (HIV) infection. The incremental direct medical costs of zidovudine therapy
were determined, and data on the effects of therapy were derived from the report of the ... Cited by 104 - Related articles - All 4 versions
JV Chancellor, AM Hill, CA Sabin, KN Simpson, M … - …, 1997 - ncbi.nlm.nih.gov The use of combination antiretroviral therapy is supported by clinical evidence for its superiority
over monotherapy. Lamivudine (3TC) has been studied in combination with zidovudine
(ZDV) and is recommended for use specifically in combination therapy. With the ... Cited by 61 - Related articles - BL Direct - All 2 versions
- ►bmj.com [PDF] EZ Oddone, P Cowper, JD Hamilton, DB Matchar, P … - British Medical Journal, 1993 - bmj.com Oslo. The cardiovascular disease study in Norwegian counties. Results from
secondscreening. Oslo: National Health Screening Service, 1988. 14 Freedman DS, Gruchow
HW, Anderson AJ, Rimm AA, Barboriak JJ. Relation of triglyceride levels to coronary ... Cited by 25 - Related articles - BL Direct - All 6 versions
J Mauskopf, L Lacey, A Kempel, K … - The American journal of …, 1998 - ncbi.nlm.nih.gov In this paper, we present a Markov model for estimating the cost-effectiveness of combination
therapy with lamivudine (LMV) and zidovudine (ZDV) compared with ZDV alone. We also compare
the predictions of the Markov model for the impact of combination therapy on trial period ... Cited by 25 - Related articles
K Simpson, EJ Hatziandreu, F Andersson, A … - …, 1994 - ncbi.nlm.nih.gov A cost-effectiveness model was developed on the basis of early clinical trial results from the US
reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to
zidovudine. This model was then adapted and applied to 5 European countries to assess ... Cited by 24 - Related articles
AD Paltiel, EH Kaplan - JAIDS Journal of Acquired Immune Deficiency …, 1991 - journals.lww.com Summary: Zidovudine (ZDV), the first FDA-approved therapy for HIV/AIDS, poses a dilemma
to the policymaker. On the one hand, ZDV extends the life of HIV-infected persons, producing
a clear benefit. On the other hand, some fear that prolonging the lives of infected ... Cited by 28 - Related articles - All 3 versions
GW Torrance, A Zipursky - Clinics in perinatology, 1984 - ncbi.nlm.nih.gov 1: Clin Perinatol. 1984 Jun;11(2):267-81. Cost-effectiveness of antepartum prevention
of Rh immunization. Torrance GW, Zipursky A. While antepartum prophylaxis of
Rh immunization is much more costly and the postpartum ... Cited by 74 - Related articles - All 2 versions
- ►adisonline.com [PDF] AH Anis, RS Hogg, W Xh, B Yip, A Palepu, JSG … - …, 1998 - ingentaconnect.com Summary The purpose of this study is to model the potential economic impact of viral load–driven
triple drug combination (including a protease inhibitor) antiretroviral therapy on incremental drug
and hospitalisation costs among individuals with HIVdisease. Individuals included in the ... Cited by 31 - Related articles - BL Direct - All 8 versions
